Potential cost savings of erythropoietin administration in end-stage renal disease
- 1 February 2002
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 112 (3) , 169-175
- https://doi.org/10.1016/s0002-9343(01)01103-2
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Subcutaneous erythropoietin therapy: Efficacy and economic implicationsAmerican Journal of Kidney Diseases, 1998
- Erythropoietin for End-Stage Renal DiseaseNew England Journal of Medicine, 1998
- The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and EpoetinNew England Journal of Medicine, 1998
- Subcutaneous Compared with Intravenous Epoetin in Patients Receiving HemodialysisNew England Journal of Medicine, 1998
- Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996Kidney International, 1998
- Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient?American Journal of Kidney Diseases, 1996
- Intravenous Versus Subcutaneous Dosing of Epoetin: A Review of the LiteratureAmerican Journal of Kidney Diseases, 1993
- Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteersBlood, 1990
- The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.British Journal of Clinical Pharmacology, 1990
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989